Chemomab Therapeutics Ltd.

NasdaqCM CMMB

Chemomab Therapeutics Ltd. Price to Earnings Ratio (P/E) on December 30, 2024: -2.63

Chemomab Therapeutics Ltd. Price to Earnings Ratio (P/E) is -2.63 on December 30, 2024, a -734.60% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Chemomab Therapeutics Ltd. 52-week high Price to Earnings Ratio (P/E) is -0.29 on January 26, 2024, which is 89.03% above the current Price to Earnings Ratio (P/E).
Chemomab Therapeutics Ltd. 52-week low Price to Earnings Ratio (P/E) is -2.66 on December 27, 2024, which is -1.10% below the current Price to Earnings Ratio (P/E).
Chemomab Therapeutics Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.12.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: CMMB

Chemomab Therapeutics Ltd.

CEO	Dr. Adi Mor George Ph.D.
IPO Date	Feb. 12, 2019
Location	Israel
Headquarters	Building 7
Employees	20
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Key trends

Past 5 years